Brazil is not out of the recessionary woods yet, but there are signs a recovery is in full swing. Foreign investors are looking at Brazil again, and one of the main industry that interest investors is the banking industry.
Even though the country is licking its wounds from the devastating recession, private Brazilian banks are making more money than ever. And Wall Street wants to get in on the action. Hedge funds in the U.S. are buying Bradesco stock, and singing the praises of the bank’s CEO, Luíz Carlos Trabuco Cappi. Trabuco is the real deal when it comes to bank experience and management skills.
Mr. Trabuco’s accomplishments are impressive by anyone’s standards. He’s been with the Bradesco since 1969. And he knows how every bank division operates because he has experience in every division of the bank. He is the man who made Bradesco’s insurance division, Banco Seguros, famous by making it a real moneymaker in 2008. After four years as president, the insurance division was the icing on the bank’s profit cake. And Seguros is one of the reasons the bank continues to be successful in terms of revenue and profit.
Luíz Carlos Trabuco Cappi is not an accountant or a finance wizard. Mr. Trabuco is a University of São Paulo alumni. He has a philosophy degree and a post-graduate degree in psychology. Trabuco is also an advocate of social and government reforms. The bank supports environmentally friendly programs and education programs that help high school students every year. Bradesco may be the second largest private bank in Brazil, but Luíz Carlos Trabuco Cappi is not a second-class bank president. The 66-year-old Trabuco knows his bank is in a position to take over as the number one private bank in Brazil. That was part of the long-term plan when Trabuco and the Board of Directors put the HSBC acquisition together in 2015. Bradesco now owns HSBC’s Brazilian division, and Trabuco was instrumental in putting the deal together. Mr. Trabuco holds a number of board positions, and he has a reputation for being one of Brazil’s honest bankers. He is not a bank president that seeks approval or recognition. He does his job, and he does it well.
Eric Lefkofsky is best known for his crucial role as a founder of Groupon, the innovative startup that allows individuals to form temporary conglomerates in order to leverage economies of scale. But he has also been involved in dozens of other projects, all of which have enjoyed varying degrees of success and more information click here.
Today, Lefkofsky has embarked on a new journey. He has undertaken what perhaps is the largest challenge of his life. He is seeking to completely transform the way medicine in general and oncology in particular is practiced, through the use of Big Data techniques.
Lefkofsky first became aware of the woeful shortcomings of modern data usage in medicine when a family member fell ill with cancer. He was struck by the fact that oncologists seemingly had less access to data and intelligence than most truck drivers. He knew from years of running data-intensive tech companies that it was possible to do much better. This formed the impetus behind his startup, Tempus and what Eric knows.
Tempus is now one of the only firms that is creating centralized data solutions and high-intelligence analytics for oncologists. The firm is developing systems that it says will someday be able to effectively act as on-the-spot meta-studies, giving oncologists the power to ask specific questions about their patients and what treatment regimes are likely to maximize survival. Tempus believes that this ability to tap into vast quantities of available data, with the analytic capabilities that were once only possible with million-dollar studies, will give oncologists and physicians a granularity in their understanding of disease processes and likely treatment outcomes that is orders of magnitude superior to anything that has come before.
Lefkofsky points out that this could usher in a revolution in cancer treatment, dramatically increasing survival for some types of cancer and reducing many of those to the level of diseases like AIDS, where patients who correctly follow treatment regimens have only slightly reduced life expediencies. Lefkoskfy believes that with the granular understanding that Tempus will bring, cancer will largely become a disease that people can live with and Eric’s lacrosse camp.
Although it isn’t exactly a cure, Lefkofksy says that reducing cancer’s mortality is the next best thing.
Other Reference: https://www.insidephilanthropy.com/guide-to-individual-donors/eric-lefkofsky.html